Literature DB >> 19590880

Inflammatory myopathy with abundant macrophages and dermatomyositis: two stages of one disorder or two distinct entities?

Anna Brunn1, Volkmar J Hans, Silke Vogelgesang, Martina Deckert.   

Abstract

Inflammatory myopathy with abundant macrophages (IMAM) and dermatomyositis (DM) are considered to represent related disorders, since they share inflammatory infiltrates and skin alterations. In order to get more insight into these disorders, we addressed the cellular composition of the inflammatory infiltrates in muscle biopsies of 11 patients with IMAM and DM. In IMAM, inflammatory infiltrates predominantly consisted of CD68+ MRP14+ macrophages which weakly expressed TNF-α, a few CD3+ T cells with a prominent IL-10 expression, and single CD123+ plasmacytoid dendritic cells. In DM, infiltrates were mainly composed of CD3+ CD4+ T cells which expressed IL-10, numerous CD123+ plasmacytoid dendritic cells, and CD20+ B cells. The low number of CD68+ macrophages was of 25F9+ late inflammatory phenotype. Membrane attack complex was expressed in necrotic muscle fibers in IMAM and on endomysial capillaries in DM, respectively. Thus, in IMAM, the inflammatory reaction markedly differed from DM. These observations may lend support to the hypothesis that IMAM and DM are distinct with respect to their pathogenesis. Whether, alternatively, these differences in the cellular composition of the infiltrates and the cytokine profile rather reflect different stages of disease, will require the analysis of a larger series.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19590880     DOI: 10.1007/s00401-009-0570-8

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  7 in total

1.  Clinical, serologic and magnetic resonance imaging of 3 cases of inflammatory myopathy with abundant macrophages in the Japanese population.

Authors:  Shintaro Hara; Tomoko Henmi; Atsushi Kawakami; Keita Fujikawa; Hiroshi Mukae; Yuji Ishimatsu; Noriho Sakamoto; Tomoyuki Kakugawa; Kenzou Kaji; Manabu Fujimoto; Masataka Kuwana; Toshiaki Tsukada; Katsuya Satoh; Masakatsu Motomura; Mami Tamai; Hideki Nakamura; Hiroaki Ida; Tomayoshi Hayashi; Tomoki Origuchi; Katsumi Eguchi; Shigeru Kohno
Journal:  Rheumatol Int       Date:  2010-12-02       Impact factor: 2.631

2.  The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy.

Authors:  Tae Chung; Lisa Christopher-Stine; Julie J Paik; Andrea Corse; Andrew L Mammen
Journal:  Muscle Nerve       Date:  2015-05-14       Impact factor: 3.217

3.  MEFV gene polymorphisms and TNFRSF1A mutation in patients with inflammatory myopathy with abundant macrophages.

Authors:  K Fujikawa; K Migita; Y Shigemitsu; M Umeda; F Nonaka; M Tamai; H Nakamura; A Mizokami; T Tsukada; T Origuchi; N Yonemitsu; M Yasunami; A Kawakami; K Eguchi
Journal:  Clin Exp Immunol       Date:  2014-11       Impact factor: 4.330

4.  Recurrent Bilateral Focal Myositis.

Authors:  Hiroko Nagafuchi; Hiromasa Nakano; Seido Ooka; Yukiko Takakuwa; Hidehiro Yamada; Mamoru Tadokoro; Sadatomo Shimojo; Shoichi Ozaki
Journal:  Intern Med       Date:  2016-11-15       Impact factor: 1.271

5.  Morin Stain Detects Aluminum-Containing Macrophages in Macrophagic Myofasciitis and Vaccination Granuloma With High Sensitivity and Specificity.

Authors:  Rati Chkheidze; Dennis K Burns; Charles L White; Diana Castro; Julie Fuller; Chunyu Cai
Journal:  J Neuropathol Exp Neurol       Date:  2017-04-01       Impact factor: 3.685

Review 6.  Pathophysiological Mechanisms and Treatment of Dermatomyositis and Immune Mediated Necrotizing Myopathies: A Focused Review.

Authors:  Renske G Kamperman; Anneke J van der Kooi; Marianne de Visser; Eleonora Aronica; Joost Raaphorst
Journal:  Int J Mol Sci       Date:  2022-04-13       Impact factor: 6.208

7.  Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies.

Authors:  Olga Kryštůfková; Sevim Barbasso Helmers; Paulius Venalis; Vivianne Malmström; Eva Lindroos; Jiří Vencovský; Ingrid E Lundberg
Journal:  Arthritis Res Ther       Date:  2014-10-10       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.